论文部分内容阅读
目的系统评价Toll样受体2(Toll like receptor 2,TLR2)基因I/D多态性与肿瘤发病风险的相关性。方法计算机检索Pub Med、EMbase、The Cochrane Library(2015年第7期)、CBM、CNKI、VIP和Wan Fang Data数据库,搜集关于TLR2基因I/D多态性与肿瘤发病风险相关性的病例-对照研究,检索时限均为建库至2015年7月。由2位评价员独立筛选文献、提取资料和评价纳入研究的偏倚风险后,采用Rev Man 5.2软件进行Meta分析。结果最终纳入13个病例-对照研究,共包括3 250例肿瘤患者和4 332例对照人群。Meta分析结果显示,TLR2基因I/D多态性与肿瘤发病风险相关[DD+DI vs.II:OR=1.60,95%CI(1.13,2.27),P=0.009;DD vs.II+DI:OR=1.73,95%CI(1.13,2.66),P=0.01;DD vs.II:OR=1.99,95%CI(1.22,3.24),P=0.006;DI vs.II:OR=1.52,95%CI(1.09,2.11),P=0.01;D vs.I:OR=1.54,95%CI(1.14,2.09),P=0.005]。结论 TLR2基因I/D多态性与肿瘤发病风险相关。受纳入研究数量及质量的限制,该结论需进一步进行验证。
Objective To evaluate the relationship between Toll - like receptor 2 (TLR2) gene I / D polymorphism and tumor risk. Methods PubMed, EMbase, The Cochrane Library (2015 Issue 7), CBM, CNKI, VIP and Wan Fang Data were searched by computer to collect case-control data on the correlation between TLR2 gene I / D polymorphism and oncological risk Research, retrieval time are building the library until July 2015. After two reviewers independently screened the literature, extracted data, and assessed the risk of being included in the study, Meta-analysis was performed using Rev Man 5.2 software. The results eventually included 13 case-control studies comprising a total of 3 250 tumor patients and 4 332 control subjects. Meta-analysis showed that the TLR2 gene I / D polymorphism was associated with the risk of developing cancer [DD + DI vs. II: OR = 1.60,95% CI (1.13,2.27), P = 0.009; OR = 1.73, 95% CI 1.13, 2.66, P = 0.01; DD vs. II: OR = 1.99, 95% CI 1.22, 3.24, P = 0.006; DI vs. II: OR = 1.52, 95% CI (1.09, 2.11), P = 0.01; D vs. I: OR = 1.54, 95% CI (1.14, 2.09), P = 0.005]. Conclusion The TLR2 gene I / D polymorphism is associated with the risk of cancer. Due to the limited number and quality of studies involved, this conclusion needs to be further verified.